2seventy bio Inc (TSVT)
4.93
+0.33
(+7.17%)
USD |
NASDAQ |
May 02, 16:00
5.00
+0.07
(+1.42%)
After-Hours: 20:00
2seventy bio Cash from Investing (TTM): 43.86M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 43.86M |
| September 30, 2023 | -12.53M |
| June 30, 2023 | -110.88M |
| March 31, 2023 | 3.802M |
| December 31, 2022 | 3.753M |
| Date | Value |
|---|---|
| September 30, 2022 | 13.27M |
| June 30, 2022 | 86.94M |
| March 31, 2022 | 33.51M |
| December 31, 2021 | -17.59M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-110.88M
Minimum
Jun 2023
86.94M
Maximum
Jun 2022
4.905M
Average
3.802M
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
| Bristol-Myers Squibb Co | -21.70B |
| Johnson & Johnson | -2.901B |
| Regeneron Pharmaceuticals Inc | -3.185B |
| Macrogenics Inc | -80.08M |
| Akebia Therapeutics Inc | 0.00 |